Anne Wojcicki wanted to run things—alone. It was 2009 and her startup 23andMe was riding high, fueled by a steady stream of ...

The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million. 23andMe's stock plummeted after a 2023 data breach exposed millions of customer accounts.

23andMe faced major hurdles in 2024, including a $30 million settlement related to compromised data. 23andMe is now restructuring its business operations to reduce costs and streamline operations.

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

Five years ago, 23andMe was one of the hottest startups in the world. Millions of people were spitting into its test tubes to ...

Following is a transcript of the video. Narrator: Hey, Siri, do I have coronavirus? Siri: A few questions can help you understand your situation. Ready to begin? Narrator: More and more tech ...

One reason for this is because the answer is that it is impossible to know for sure. Your data is at risk, but the extent to which it is at risk is unclear. But there are facts, law and precedent ...

Me (ME) has been quietly exploring a possible sale of its telehealth business, Lemonaid, according to Business Insider.Stay Ahead of the ...

When evaluating 23andMe's stock performance and future outlook, investors should consider short-term market trends and long-term growth potential. This analysis will dive into recent stock metrics ...

The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer ...

23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million.